Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well ...

VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 ...

Portfolio manager Dan LeVan heads Trivalent, a Boston-based international equity boutique that specializes in non-US developed- and emerging-markets strategies under Victory Capital's umbrella.

In a significant boost to the nation's poultry industry, Boehringer Ingelheim has announced the launch of its innovative ...

In 1978, the first trivalent vaccine included two influenza A strains and one influenza B strain. Currently, there are two influenza B lineages circulating; in the latest WHO recommendations ...

Triple click chemistry has revolutionized chemical synthesis with its simplicity and efficiency, allowing for the quick and selective assembly of complex molecules. Now, in a recent study, researchers ...

For adults, who have had organ transplants between the ages of 18–64 years, or those on immunosuppressive medications, the shots will include: HD-IIV3 with trivalent high dose inactivated ...

The Fund seeks long-term growth of capital. The Fund invests at least 80% of its assets in securities of small- to mid-capitalization companies.

Background Because inactivated trivalent influenza vaccines (TIVs) contain 1 influenza B strain, whereas 2 lineages may co-circulate, B lineage mismatch is frequent. We assessed an inactivated ...

Portfolio manager Dan LeVan heads Trivalent, a Boston-based international equity boutique that specializes in non-US developed- and emerging-markets strategies under Victory Capital's umbrella.

With VAXXITEK® HVT+IBD+H5, Boehringer Ingelheim is expanding its proven VAXXITEK® range with a new vaccine that protects ...